Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06824363 · ClinicalTrials.gov registry record · Early Phase 1
ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu
A Early Phase 1 study, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 34
- Enrollment target
NCT06824363 is a Early Phase 1 study that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 34 participants.
The verdict
NCT06824363, a Early Phase 1 study, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a proof of principle clinical trial determining efficacy of single dose dualimmune checkpoint inhibitors to increase intra-tumoral T cells in esophageal, gastroesophageal junction, and gastric adenocarcinomas. These are subjects who have not previously been treated for their disease, who are willing to undergo biopsy procedures, who's disease has not spread to other parts of the body, who's tumors have ARID1A mutations.
Interventions
- DRUG Durvalumab
- DRUG Tremelimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2026-05-25 |
| Est. Completion | 2028-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06824363
The ClinicalTrials.gov registry entry for NCT06824363 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Durvalumab is the first listed.
NCT06824363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06824363 about?
NCT06824363 is a clinical study titled "ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu". This is a proof of principle clinical trial determining efficacy of single dose dualimmune checkpoint inhibitors to increase intra-tumoral T cells in esophageal, gastroesophageal junction, and gastric adenocarcinomas. These are subjects who have not previously been treated for their disease, who are...
What is the current status of trial NCT06824363?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 34 participants. The study started on 2026-05-25. Estimated completion is 2028-07.
What interventions are being tested in trial NCT06824363?
The interventions under investigation include: Durvalumab (DRUG), Tremelimumab (DRUG).
Who is sponsoring clinical trial NCT06824363?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.